Showing results (1-10 of 14) with videos related to
Sort By:
Pageof 2
Antibodies (Basel, Switzerland)|April 25, 2022
Special Issue "Antibody Engineering for Cancer Immunotherapy"Silvia Crescioli, Ann L White, Sophia N KaragiannisBlood|January 15, 2016
Influence of immunoglobulin isotype on therapeutic antibody functionStephen A Beers, Martin J Glennie, Ann L WhiteCurrent Topics in Microbiology and Immunology|August 14, 2014
FcγRIIB as a key determinant of agonistic antibody efficacyAnn L White, Stephen A Beers, Mark S CraggEuropean Journal of Immunology|July 25, 2008
CD11c provides an effective immunotarget for the generation of both CD4 and CD8 T cell responsesFernanda V V Castro, Alison L Tutt, Ann L White, et al.Cancer Immunology, Immunotherapy : CII|April 2, 2013
FcγRΙΙB controls the potency of agonistic anti-TNFR mAbsAnn L White, H T Claude Chan, Ruth R French, et al.Journal of Lipid Research|April 18, 2003
The amino acid sequences of the carboxyl termini of human and mouse hepatic lipase influence cell surface associationRobert J Brown, Joshua R Schultz, Kerry W S Ko, et al.Clinical and Experimental Immunology|March 16, 2025
FcγRIIB (CD32B) antibodies enhance immune responses through activating FcγRsAlexander P Simpson, Robert J Oldham, Kerry L Cox, et al.Immunology|May 15, 2010
Ligation of CD11c during vaccination promotes germinal centre induction and robust humoral responses without adjuvantAnn L White, Alison L Tutt, Sonya James, et al.Journal of Immunology (Baltimore, Md. : 1950)|July 12, 2011
Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibodyAnn L White, H T Claude Chan, Ali Roghanian, et al.Cancer Cell|May 23, 2020
Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor ActivityXiaojie Yu, H T Claude Chan, Hayden Fisher, et al.Pageof 2